title: V-ATPase inhibitors and implication in cancer treatment.
abstract: Acidity is one of the main features of the tumors. The V-ATPase is the primary responsible for the control of tumor microenvironment by proton extrusion to the extracellular medium. The acid environment favors tissue damage, activation of destructive enzymes in the extracellular matrix, the acquisition of metastatic cell phenotypes as well as increasing the destructive capacity. The application of specific inhibitors of V-ATPases, can decrease the acidity of tumor and may allow the reduction of tumor metastasis, acting on the survival of tumor cells and prevent the phenomena of chemoresistance. Among the most important inhibitors can be distinguished benzolactone enamides (salicylihalamide), lobatamide A and B, apicularen, indolyls, oximidine, macrolactone archazolid, lobatamide C, and cruentaren. The latest generation of inhibitors includes NiK12192, FR202126, and PPI SB 242784. The purpose of this paper is to describe the latest advances in the field of V-ATPase inhibitors, describe further developments related to the classic inhibitors, and discuss new potential applications of these drugs in cancer treatment.
authors.affiliation: Entrerríos s/n, Santiago de Compostela C.P. 15782, Spain. perezsayans@gmail.com
authors.forename: Mario
authors.initials: M
authors.lastname: Pérez-Sayáns
authors.forename: José Manuel
authors.initials: JM
authors.lastname: Somoza-Martín
authors.forename: Francisco
authors.initials: F
authors.lastname: Barros-Angueira
authors.forename: José Manuel Gándara
authors.initials: JM
authors.lastname: Rey
authors.forename: Abel
authors.initials: A
authors.lastname: García-García
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology / Q000627:therapeutic use; D002470:Cell Survival; D019008:Drug Resistance, Neoplasm; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D018942:Macrolides / Q000494:pharmacology / Q000627:therapeutic use; D025262:Vacuolar Proton-Translocating ATPases / Q000037:antagonists & inhibitors*
chemical_list: D000970:Antineoplastic Agents; D019086:Bridged Bicyclo Compounds, Heterocyclic; D004791:Enzyme Inhibitors; D018942:Macrolides; C410986:salicylihalamide A; D025262:Vacuolar Proton-Translocating ATPases